MediciNova, Inc.

Informe acción NasdaqGM:MNOV

Capitalización de mercado: US$62.5m

MediciNova Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de MediciNova de 66.7% y 70.1% respectivamente, mientras que el BPA crecerá en un 65.9% al año.

Información clave

66.7%

Tasa de crecimiento de los beneficios

65.92%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs24.9%
Tasa de crecimiento de los ingresos70.1%
Rentabilidad financiera futuran/a
Cobertura de analistas

Low

Última actualización08 Jun 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Artículo de análisis • Aug 28

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Apr 19

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Artículo de análisis • Nov 27

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Artículo de análisis • Jul 11

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Mar 18

Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Oct 12

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 15

MediciNova to get US patent for MN-166 to treat brain cancer

MediciNova (NASDAQ:MNOV) said it will receive a new patent from the U.S. Patent and Trademark Office which covers MN-166 (ibudilast) to treat glioblastoma. The new patent is expected to expire no earlier than February 2039, the company said in a Sept. 14 press release. Glioblastoma is a type of cancer that can occur in the brain or spinal cord. The allowed claims cover a method of treating a patient with glioblastoma or recurrent glioblastoma wherein a patient expresses unmethylated MGMT, using MN-166 (ibudilast) in combination with one or more other therapeutic agents. "Results of our glioblastoma animal model study showed that median survival was longer in the group that received combination treatment with MN-166 plus temozolomide compared to the group that received the standard treatment of temozolomide alone," said MediciNova Chief Medical Officer Kazuko Matsuda.
Seeking Alpha • Aug 16

MediciNova's MN-166 to be part of study to treat Long COVID

MediciNova (NASDAQ:MNOV) said it plans to participate in a grant-funded clinical trial, dubbed RECLAIM, to evaluate MN-166 (ibudilast) and other therapies for treating Long COVID. The company added that it reached an agreement to collaborate with the University Health Network.
Seeking Alpha • Jul 22

MediciNova begins study of parenteral formulation of MN-166

MediciNova (NASDAQ:MNOV) said it started a first-in-human study of a new parenteral formulation of MN-166 (ibudilast). The company said the newly developed MN-166 (ibudilast) formulation will provide an additional option besides the current oral formulation. "With MN-166 expected to be effective to treat a variety of diseases, we believe expanding to a parenteral formulation increases the feasibility of treating more target indications, thus increasing the value of MN-166," said MediciNova Chief Medical Officer Kazuko Matsuda. In April, the company reported data from a phase 2 trial of MN-166 for alcohol use disorder, showing that the drug reduced alcohol craving on non-drinking days.
Seeking Alpha • Jun 30

MediciNova announces extension of BARDA contract for Ibudilast development

MediciNova (NASDAQ:MNOV) said on Wednesday that a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for its small molecule candidate MN-166 (ibudilast). Under the partnership with BARDA, the company will repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). The contract was amended to extend the period of performance until March 2023. BARDA, a division of the U.S. Department of Health and Human Services will fund the proof-of-concept studies in preclinical models of chlorine gas-induced acute lung injury. The project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority. Last year in March, MediciNova jumps on BARDA partnership for Ibudilast development. Shares are up 2.75% after-hours.
Artículo de análisis • Mar 19

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Artículo de análisis • Nov 23

MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 31

MediciNova: The Pain Of A Positive Outlook

MediciNova reported blasé Q2 2021 earnings on 08/12/2021. MediciNova's core pipeline consists of two candidate therapies being developed in treatment of eleven indications. MediciNova's MS program is a high potential, late stage program which has been in stall mode. MediciNova has operated under less financial strain than expected for a company with its advanced pipeline.
Seeking Alpha • Jun 21

MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study

MediciNova (MNOV) soars 30.6% premarket after announcing positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder ((AUD)), published in Nature’s Translational Psychiatry. The Phase 2 trial evaluated the effect of 14 days of ibudilast treatment on mood, heavy drinking, and neural reward signals in individuals with AUD. A total of 52 patients were enrolled. Key results include: Ibudilast did not have a significant effect on negative mood.Ibudilast, relative to placebo, reduced the odds of heavy drinking across time
Artículo de análisis • May 15

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:MNOV - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/2028435N/AN/A2
12/31/20270-22N/AN/A2
12/31/20260-14N/AN/A2
3/31/20261-12-10-9N/A
12/31/20250-12-10-10N/A
9/30/20250-12-10-10N/A
6/30/20250-12-10-10N/A
3/31/2025N/A-11-11-11N/A
12/31/2024N/A-11-11-11N/A
9/30/2024N/A-10-9-9N/A
6/30/20241-8-9-9N/A
3/31/20241-8-8-8N/A
12/31/20231-9-7-7N/A
9/30/20231-10-11-11N/A
6/30/2023N/A-12-12-12N/A
3/31/2023N/A-14-12-12N/A
12/31/2022N/A-14-13-13N/A
9/30/2022N/A-13-13-13N/A
6/30/20220-13-13-13N/A
3/31/20220-13-9-9N/A
12/31/20214-10-9-9N/A
9/30/20214-11-8-8N/A
6/30/20214-11-9-9N/A
3/31/20214-11-12-12N/A
12/31/2020N/A-14-11-11N/A
9/30/2020N/A-13-11-11N/A
6/30/2020N/A-12-9-9N/A
3/31/2020N/A-11-9-9N/A
12/31/2019N/A-13N/A-9N/A
9/30/2019N/A-11N/A-8N/A
6/30/2019N/A-16N/A-8N/A
3/31/2019N/A-15N/A-8N/A
12/31/2018N/A-15N/A-9N/A
9/30/2018N/A-16N/A-9N/A
6/30/2018N/A-13N/A-9N/A
3/31/2018N/A-13N/A-8N/A
12/31/2017N/A-11N/A-7N/A
9/30/2017N/A-11N/A-7N/A
6/30/2017N/A-10N/A-7N/A
3/31/2017N/A-11N/A-7N/A
12/31/2016N/A-11N/A-7N/A
9/30/2016N/A-12N/A-7N/A
6/30/2016N/A-11N/A-7N/A
3/31/2016N/A-10N/A-6N/A
12/31/2015N/A-9N/A-7N/A
9/30/2015N/A-8N/A-7N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que MNOV sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (3.5%).

Beneficios vs. Mercado: Se prevé que MNOV sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que MNOV sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (70.1% al año) de MNOV crezcan más rápidamente que los del mercado US (12.5% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (70.1% al año) de MNOV crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MNOV se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/06/11 00:32
Precio de las acciones al final del día2026/06/11 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

MediciNova, Inc. está cubierta por 8 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Jason KolbertD. Boral Capital LLC.
Lander Egaña-GorroñoH.C. Wainwright & Co.
Elemer PirosLucid Capital Markets